Literature DB >> 19005412

Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin.

Sebastiaan Heidt1, Dave L Roelen, Chantal Eijsink, Cees van Kooten, Frans H J Claas, Arend Mulder.   

Abstract

BACKGROUND: Humoral immunity is increasingly recognized as an important factor in the rejection of organ transplants. In general, humoral rejection is treated with standard immunosuppressive drugs. The direct effect of these immunosuppressive drugs on B cells is not well known.
METHODS: Purified human B cells devoid of T cells were stimulated with CD40L expressing L cells, or by anti-CD40 mAb with or without Toll-like receptor triggering, all in the presence of B-cell activating cytokines. These three protocols resulted in various degrees of B-cell stimulation. We added four commonly used immunosuppressive drugs (tacrolimus, cyclosporin, mycophenolic acid [MPA], and rapamycin) to these cultures and tested a variety of parameters of B-cell activity including proliferation, apoptosis induction, and both IgM and IgG production.
RESULTS: Tacrolimus and cyclosporin marginally inhibited B-cell proliferation and immunoglobulin production, and the extent of inhibition depended on the degree of the B-cell stimulation. In contrast, MPA and rapamycin profoundly inhibited both B-cell proliferation and immunoglobulin production, which was independent of the degree of B-cell stimulation. Both drugs induced B-cell apoptosis. Moreover, rapamycin caused a reduction in the number of B cells capable of producing immunoglobulins.
CONCLUSIONS: Our data show that MPA and rapamycin are capable of strongly inhibiting B cells responses. This provides a rationale for the use of both MPA and rapamycin to prevent or counteract humoral responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005412     DOI: 10.1097/TP.0b013e3181874a36

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  43 in total

Review 1.  Ras family of small GTPases in immunity and inflammation.

Authors:  Derek S Johnson; Youhai H Chen
Journal:  Curr Opin Pharmacol       Date:  2012-03-07       Impact factor: 5.547

2.  In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Nikolaos Antoniadis; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2017-05-15       Impact factor: 2.370

3.  Changing face of vaccination in immunocompromised hosts.

Authors:  Daire O'Shea; Lukas A Widmer; Jörg Stelling; Adrian Egli
Journal:  Curr Infect Dis Rep       Date:  2014-09       Impact factor: 3.725

4.  Preparation of hybrid porcine thymus containing non-human primate thymic epithelial cells in miniature swine.

Authors:  Mitsuhiro Sekijima; Hisashi Sahara; Akira Shimizu; Takehiro Iwanaga; Takahiro Murokawa; Yuichi Ariyoshi; Thomas Pomposelli; Mohsen Khosravi Maharlooei; Megan Sykes; Kazuhiko Yamada
Journal:  Xenotransplantation       Date:  2019-07-10       Impact factor: 3.907

5.  Calcineurin inhibitors dampen humoral immunity by acting directly on naive B cells.

Authors:  R De Bruyne; D Bogaert; N De Ruyck; B N Lambrecht; M Van Winckel; P Gevaert; M Dullaers
Journal:  Clin Exp Immunol       Date:  2015-06       Impact factor: 4.330

6.  Polyclonal B cell activation for accurate analysis of pre-existing antigen-specific memory B cells.

Authors:  G E Karahan; M Eikmans; J D H Anholts; F H J Claas; S Heidt
Journal:  Clin Exp Immunol       Date:  2014-07       Impact factor: 4.330

7.  Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.

Authors:  Caron A Jacobson; Lixian Sun; Haesook T Kim; Sean M McDonough; Carol G Reynolds; Michael Schowalter; John Koreth; Corey S Cutler; Vincent T Ho; Edwin P Alyea; Philippe Armand; Bruce R Blazar; Robert J Soiffer; Joseph H Antin; Jerome Ritz; Stefanie Sarantopoulos
Journal:  Biol Blood Marrow Transplant       Date:  2014-01-23       Impact factor: 5.742

8.  Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help.

Authors:  S Heidt; D L Roelen; C Eijsink; M Eikmans; C van Kooten; F H J Claas; A Mulder
Journal:  Clin Exp Immunol       Date:  2009-11-18       Impact factor: 4.330

9.  mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells.

Authors:  Christina L Avila; Jason M Zimmerer; Steven M Elzein; Thomas A Pham; Mahmoud Abdel-Rasoul; Ginny L Bumgardner
Journal:  Transplantation       Date:  2016-09       Impact factor: 4.939

Review 10.  Immunoregulatory functions of mTOR inhibition.

Authors:  Angus W Thomson; Hēth R Turnquist; Giorgio Raimondi
Journal:  Nat Rev Immunol       Date:  2009-05       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.